Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

62.98 -2.62 (-3.99%)

Delayed Quote Updated: 2:31 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference ↗

September 25, 2026

Cytokinetics (NASDAQ:CYTK) executives outlined the company’s commercial expansion plans, cardiovascular pipeline and business-development priorities during a Bernstein investor symposium, highlighting...

Via MarketBeat

If You Invested $1000 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today ↗

September 11, 2026

Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 10.3% on an annualized basis producing an average annual return of 23.89%. Currently, Cytokinetics has a market...

Via Benzinga

If You Invested $100 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today ↗

August 28, 2026

Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 7.78% on an annualized basis producing an average annual return of 21.28%. Currently, Cytokinetics has a market...

Via Benzinga

Cytokinetics’ Aficamten Hits Dual Phase III Endpoints in Non-Obstructive HCM ↗

August 28, 2026

Cytokinetics (NASDAQ:CYTK) presented primary results from its Phase III ACACIA-HCM trial evaluating aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, or nHCM,...

Via MarketBeat

Cytokinetics (NASDAQ:CYTK) Beats Q2 Estimates on Strong MYQORZO Launch ↗

August 06, 2026

Via Chartmill

Cytokinetics Inc. (NASDAQ:CYTK) Scores Strong Setup Quality for a Potential Breakout ↗

April 23, 2026

Via Chartmill

Cytokinetics Inc (NASDAQ:CYTK) Reports Strong Q4 Revenue Beat Amid Deepening Losses and Negative Market Reaction ↗

February 24, 2026

Via Chartmill

CYTOKINETICS INC (NASDAQ:CYTK) Shows Strong Technicals and High-Quality Breakout Setup ↗

February 14, 2026

Via Chartmill

Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700 ↗

August 22, 2026

Blum exercised stock options at $10.60 and sold at $76.76, capturing significant appreciation.

Via The Motley Fool

Topics Regulatory Compliance

Cytokinetics (CYTK) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

MYQORZO captures 40% new-to-brand share with 1,500 dispensed patients.

Via The Motley Fool

Topics Earnings Economy

Cytokinetics Q2 Earnings Call Highlights ↗

August 06, 2026

Cytokinetics (NASDAQ:CYTK) reported second-quarter results marked by early commercial momentum for MYQORZO, international market-access progress and plans to seek an expanded indication for aficamten...

Via MarketBeat

Topics Earnings

Here's How Much $100 Invested In Cytokinetics 10 Years Ago Would Be Worth Today ↗

August 05, 2026

Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 7.02% on an annualized basis producing an average annual return of 20.46%. Currently, Cytokinetics has a market...

Via Benzinga

Prediction: U.S. Small-Cap Stocks Will Beat Large Caps for 10 Years ↗

July 21, 2026

If you want to lock in future gains from today's small-cap stocks, these two ETFs could be good options.

Via The Motley Fool

Topics ETFs

What This Cytokinetics Insider Sale Might Mean With the Stock Up 110% ↗

July 14, 2026

Blum exercised options at $10.60 per share and immediately sold them at $82.02, capturing gains from a 122% stock surge over the past year. He retains 381,986 shares and maintains a 0.31% ownership...

Via The Motley Fool

Topics Regulatory Compliance

Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise ↗

May 22, 2026

Cytokinetics (NASDAQ:CYTK) executives said the commercial launch of MYKORZO is tracking ahead of internal expectations, while also highlighting positive physician feedback on the drug’s label, REMS...

Via MarketBeat

Cytokinetics (CYTK) Q1 2026 Earnings Transcript ↗

May 05, 2026

Cytokinetics (CYTK) Q1 2026 Earnings Transcript

Via The Motley Fool

Wondering what's happening in today's pre-market session? ↗

May 05, 2026

Via Chartmill

Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗

March 23, 2026

This clinical-stage biotech focuses on developing therapies for neurological and immunoscience disorders.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset ↗

March 21, 2026

This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.

Via The Motley Fool

Topics Regulatory Compliance

This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth ↗

March 21, 2026

This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.

Via The Motley Fool

Topics Regulatory Compliance

This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash ↗

March 21, 2026

Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date.

Via The Motley Fool

Topics Regulatory Compliance

DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗

March 21, 2026

iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but...

Via The Motley Fool

Topics Derivatives ETFs Regulatory Compliance

This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year ↗

March 20, 2026

This clinical-stage biotech develops therapies for serious immunological diseases, with a focus on late-stage biologic candidates.

Via The Motley Fool

Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market ↗

March 09, 2026

This biopharma company advancing cardiac drug candidates disclosed a notable insider sale amid late-stage clinical development.

Via The Motley Fool

Topics Regulatory Compliance

Cytokinetics (CYTK) Q4 2025 Earnings Transcript ↗

February 24, 2026

Cytokinetics (CYTK) Q4 2025 Earnings Transcript

Via The Motley Fool

European Commission Grants Marketing Authorization to Cytokinetics for Cardiac Drug MYQORZO

February 23, 2026

In a landmark decision for the cardiovascular treatment landscape, the European Commission (EC) officially granted marketing authorization to Cytokinetics, Inc. (Nasdaq: CYTK) on February 17, 2026, for...

Via MarketMinute

Topics Intellectual Property

Cytokinetics Secures Triple Crown: EU Approval of MYQORZO Solidifies Global Reach in Cardiovascular Market

February 19, 2026

Cytokinetics, Inc. (Nasdaq: CYTK) has officially cleared its final major regulatory hurdle for its flagship heart failure drug, MYQORZO (aficamten), receiving marketing authorization from the European...

Via MarketMinute

The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors

January 22, 2026

From The Law Offices of Frank R. Cruz

Via Business Wire

Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf

January 08, 2026

From Grabar Law Office

Via GlobeNewswire

The $5.1 Trillion Wave: Why 2026 is Set to Become the Biggest Year for Global M&A

January 16, 2026

As the global economy shakes off the final remnants of the high-interest-rate era, a massive wave of consolidation is sweeping through corporate boardrooms. Analysts have officially adjusted their...

Via MarketMinute

Topics Artificial Intelligence Economy

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.